Difference between revisions of "Tivantinib (ARQ-197)"
Warner-admin (talk | contribs) |
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
||
| Line 23: | Line 23: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| − | [[Category:Oral | + | [[Category:Oral medications]] |
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
Revision as of 17:31, 25 July 2017
General information
Class/mechanism: C-Met inhibitor. Inappropriate or constitutive activation of the receptor tyrosine kinase c-Met and its signalling pathway is implicated in many cancers, playing a role in abnormal proliferation, survival, invasion, metastasis, and angiogenesis.[1]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Clinical trials
- Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffein, Midazolam, and Digoxin in Cancer Subjects
- Tivantinib in Treating Patients With Metastatic Prostate Cancer
- c-Met Inhibitor ARQ 197 (Tivantinib) in Treating Patients With Relapsed Multiple Myeloma
- Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer
- ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors
- ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
- ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Patient drug information
No information available.